About us
Sustained Therapeutics is a clinical-stage pharmaceutical company developing innovative sustained-release drug delivery platforms
Our Focus
Fast translation of technologies into the clinic to help patients with pain and cancer.
Our Platform
Sustained-release platforms for the targeted delivery of pain medications and cancer therapeutics.
Our Goal
Make existing safe and effective drugs better by combining them with our delivery platforms.
Leadership Team
Dr. Martin Gleave, MD
Founder & Chief Medical Officer
Dr. Gleave is a Distinguished Professor and Chair of the Department of Urologic Sciences at the University of British Columbia. A clinician-scientist and urologic surgeon who has published more than 600 research papers, Dr. Gleave has raised over $120M in funding and co-founded biopharma startup OncoGenex, which was successfully acquired in 2017. In 2018, he was appointed to the Order of Canada for his research into cancer treatment resistance and developing new treatments for prostate cancer.
Dr. Graeme Boniface, PhD
Founder & Chief Operating OfficerDr. Boniface has spent more than 20 years in drug development in both the private and public sectors. Since 2008, he has been the COO of the Vancouver Prostate Centre, a world-renown cancer research and treatment facility. Prior to this he was the Senior Director of Clinical Research at QLT Inc. where he oversaw the development of multiple drug platforms that received FDA, Health Canada, and European agency approvals.
William Annett
Chief Executive Officer
Mr. Annett is a highly experienced leader with a successful track record in the life sciences industry. He has been CEO of four early stage companies, taking two of them public and exiting a third via acquisition. He was also a Partner at Accenture, where he led the West Coast Life Sciences practice. In addition he spent eight years at Genentech where he led the Launch Office, directed the Project Finance function supporting all Development pipeline products, and led numerous large operational transformation projects. Mr. Annett received his MBA from the Harvard Business School.
Board of Directors
Carol A. Ammon, BSN, MBA
Retired CEO and Chair,Endo Pharmaceuticals Inc.
Carol A. Ammon is the founder and retired chief executive officer and chairman of Endo Pharmaceuticals Inc., a specialty pharmaceutical company based in Chadds Ford, Penn. In May 2005, Ms. Ammon retired as CEO after serving in that position since 1997.
Before she founded Endo Pharmaceuticals, Ms. Ammon spent 23 years in the pharmaceutical division of E.I. du Pont de Nemours and Company where she served in positions of increasing responsibility across research and development, finance, manufacturing, and sales and marketing.
In 1993, Ms. Ammon was appointed president of the generic pharmaceutical business unit of the DuPont Merck Pharmaceutical Company, the pharmaceutical joint venture of DuPont and Merck and Company, Inc. In 1996, she was named president of the U.S. Pharmaceuticals Division of DuPont Merck. As president, she was responsible for a significant share of DuPont Merck’s corporate revenue and earnings.
Ms. Ammon was named the CEO of the Year in 2004 by the Eastern Technology Council, an organization of 800 technology and life sciences companies in the Philadelphia region. The award recognizes a recipient’s leadership qualities, impact in the company’s industry and/or market, achievement of financial and other significant milestones, success in executing an operating strategy, and community industry involvement. Under her leadership, Endo also was the Eastern Technology Council’s Company of the Year in 2003. Ms. Ammon also received the 2003 Greater Philadelphia Ernst & Young Entrepreneur of the Year Award in the Health Sciences category. Ms. Ammon was chosen as the winner of the 2005 Paradigm Award and received the Woman of Spirit Award from the Greater Delaware Valley Chapter of the National Multiple Sclerosis Society. Ms. Ammon was named an Innovator of the Year by Jefferson University in 2022.
She is a former chair of the Myeloma Center Advisory Board; a trustee of Christiana Care Health System and The University of Delaware; former vice president of the board of trustees of the Hagley Museum in Wilmington, Del.; and a former member of the Harvard Healthcare Advisory Board. Ms. Ammon is also a Director at Sustained Therapeutics, a clinical stage company in British Columbia, Canada and is a Director of the Gene Editing Institute in Wilmington, Delaware.
A native of New Hyde Park, N.Y., Ms. Ammon earned a Bachelor of Arts in Biology from Central Connecticut State University. She also holds a Master of Business Administration from Adelphi University and completed the Advanced Management Program at Harvard University in 1995. She was awarded the degree of Doctor of Laws, honoris causa from Adelphi University in May of 2010 and an honorary Doctor of Science from Central Connecticut State University in 2009. She received honorary doctorates from the Thomas Jefferson University and The University of Delaware. Ms. Ammon earned her BSN, MSN, and DNP from Thomas Jefferson University 2017-2021.
Dr. Martin Gleave, MD
Founder & Chief Medical Officer
Dr. Gleave is a Distinguished Professor and Chair of the Department of Urologic Sciences at the University of British Columbia. A clinician-scientist and urologic surgeon who has published more than 600 research papers, Dr. Gleave has raised over $120M in funding and co-founded biopharma startup OncoGenex, which was successfully acquired in 2017. In 2018, he was appointed to the Order of Canada for his research into cancer treatment resistance and developing new treatments for prostate cancer.
Dennis Parolin
Solicitor, Parolin Consulting Law Corporation
Mr. Parolin is a commercial lawyer. He was a founding partner of McClellan, Rubenstein & Parolin, which was formed in 1994, and continued that firm’s practice by way of its successor firm, Parolin & Company, until 2013. He is currently providing legal and advisory services through his law corporation, Parolin Consulting Law Corporation. Mr. Parolin obtained a Bachelor of Arts degree in 1984, and a Bachelor of Laws degree in 1987, from Queen’s University.
Howard M. Glase
Howard has over twenty-five years of Canadian and U.S. corporate pharmaceutical senior commercial management experience. Howard has also gained pharmaceutical experience as a founder and CEO of Verity Pharmaceuticals and co-founder of POINT Global BioPharma Global Inc.. Moreover, Howard was a founder and CEO of a medical market research company (MD Analytics Inc), and a scientific communications and medical education business which launch Medscape/WebMD in Canada.
For the past fifteen years, Howard has focused his entrepreneurial passion in developing healthcare businesses in the biotech and pharmaceutical industries. The successful entrepreneurial ventures included successful collaborations and license agreements with Multinational companies from India, Germany, Spain, Italy and USA. Howard has also been involved in providing healthcare consultation services to Canadian, American, and Internationally based pharmaceutical companies.
Howard studied at the University of Ottawa in Kinesiology and Medical Health Sciences and completed a corporate-sponsored MBA certificate program in finance at Princeton University, NJ, and an executive MBA diploma course in International Business at the University of Western Ontario, London, Ontario.
Medical Advisory Board and Consultants
Dr. Curtis Nickel, MD
Professor, Clinician Scientist, Kingston (KGHRI)
Dr. Marie Pinizzotto, MD
Obstetrician-gynecologist,
Wilmington, Delaware
Dr. Keith Jarvi, MD
Professor, Division of Urology, University of Toronto
Dr. Michael Rowbotham, MD
Professor, Department of Anesthesia and Perioperative Care, University of California
